Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18369670 | 0.84 | PSMD14 (0.51) | KDM4EALOX15HTTALDH1A1SLC40A1 | |
| SCHEMBL29046675 | 0.84 | KDM4E (0.55) | KDM4EALOX15HTTALDH1A1SLC40A1 | |
| SCHEMBL24338474 | 0.82 | KDM4E (0.50) | KDM4EALOX15HTTALDH1A1SLC40A1 | |
| SCHEMBL4602037 | 0.81 | ALDH1A1 (0.53) | KDM4EALOX15ALDH1A1TDP1EGLN1 | |
| SCHEMBL20392682 | 0.80 | PARP1 (0.63) | KDM4EALDH1A1TDP1L3MBTL1PARP1 | |
| SCHEMBL27903815 | 0.80 | KDM4E (0.48) | KDM4EALOX15HTTALDH1A1SLC40A1 | |
| SCHEMBL17596193 | 0.80 | KDM4E (0.48) | KDM4EALOX15HTTALDH1A1SLC40A1 | |
| SCHEMBL344528 | 0.80 | ALDH1A1 (0.65) | KDM4EALOX15HTTALDH1A1SLC40A1 | |
| SCHEMBL9125289 | 0.79 | PSMD14 (0.50) | KDM4EALDH1A1PSMD14TDP1PARP1 | |
| SCHEMBL29449220 | 0.79 | KDM4E (0.47) | KDM4EALOX15HTTALDH1A1SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024059216-A2 | 6,6 SOUTHWESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| US-20200131159-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | NIH-DEITR | 2020-04-30 | — | — | US | disclosed |
| EP-3569596-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| EP-3423435-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-109153643-A | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2019-01-04 | — | — | CN | disclosed |
| US-9533982-B2 | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators | VANDERBILT UNIVERSITY (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533982-B2 | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators | VANDERBILT UNIVERSITY (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150266866-A1 | Substituted Bicyclic Heteroaryl Carboxamide Analogs As Mglur5 Negative Allosteric Modulators | VANDERBILT UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
| US-20150266866-A1 | Substituted Bicyclic Heteroaryl Carboxamide Analogs As Mglur5 Negative Allosteric Modulators | VANDERBILT UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885ALOX15 3067/4885HTT 1459/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885ALOX15 3067/4885HTT 1459/4885 |
| US-20150266866-A1 | Substituted Bicyclic Heteroaryl Carboxamide Analogs As Mglur5 Negative Allosteric Modulators | GRM5, GRIK5, GRM2 | KDM4E 1020/4885ALOX15 3498/4885HTT 413/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885ALOX15 3067/4885HTT 1459/4885 |
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM4E 3912/4885ALOX15 1888/4885HTT 2874/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | KDM4E 2031/4885ALOX15 4600/4885HTT 2767/4885 |
| US-20200131159-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | KDM4E 1530/4885ALOX15 4561/4885HTT 862/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885ALOX15 3067/4885HTT 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.